Talzenna (talazoparib capsules and liquid-filled soft gelatin capsules) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has recurrent or metastatic breast cancer
• Patient has germline BRCA mutation-positive disease

Approval duration

1 year